ICU Medical achieved dramatic financial turnaround with revenue surging 814% to $1.2M, net losses improving 51% to -$12.2M, and stockholders equity swinging from negative $2.2M to positive $10.4M.
This represents a fundamental transformation in ICU's financial position, moving from negative equity to positive capitalization while demonstrating strong revenue growth momentum. The substantial debt reduction of 46% combined with improved operating performance suggests the company has successfully addressed previous financial distress and is positioned for growth.
ICU experienced exceptional financial improvement across all major metrics, with revenue exploding 814% to $1.2M and net losses cut in half to -$12.2M. The balance sheet transformation was equally dramatic, with stockholders equity improving by 577% from negative territory to $10.4M positive, while total debt declined 46% and assets grew 204% to $14.2M. This comprehensive financial turnaround signals a company emerging from distress with strengthened capitalization, reduced leverage, and accelerating commercial traction.
Strong top-line growth of 814.1% — accelerating demand or successful expansion into new markets.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Equity base grew 577.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Current assets grew 260.6% — improving short-term liquidity or inventory/receivables build.
Asset base grew 204% — expansion through organic growth, acquisitions, or capital deployment.
Receivables surged 111.6% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Net income grew 51.1% — bottom-line growth signals improving overall business health.
Debt reduced 45.9% — deleveraging strengthens balance sheet and reduces financial risk.
Liabilities reduced 45.3% — deleveraging improves balance sheet strength and financial flexibility.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →